Literature DB >> 9349343

Epstein-Barr virus-associated lymphoproliferative eruption with progression to large granular lymphocytic leukaemia.

K H Cho1, C W Kim, O S Kwon, S G Yang, K C Park, M H Park, H I Cho, J G Kim.   

Abstract

A 12-year-old Korean girl gave a 9-year history of recurrent necrotizing papules and vesicles on the face, scalp and extremities. Skin biopsy specimens showed an atypical lymphoreticular infiltrate with vasculitis in the dermis and subcutis. In situ hybridization demonstrated latent infection by Epstein-Barr virus (EBV) of the lymphoid cells in the dermis. The disease was diagnosed as an EBV-associated lymphoproliferative skin eruption presenting as recurrent necrotic papulovesicles. The patient subsequently developed large granular lymphocytic leukaemia of natural killer cell origin. Our observations suggest that a patient with an EBV-associated lymphoproliferative skin eruption presenting with recurrent necrotic papulovesicles might progress to develop leukaemia as well as lymphoma.

Entities:  

Mesh:

Year:  1997        PMID: 9349343

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  3 in total

1.  Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia.

Authors:  Michael J Clemente; Marcin W Wlodarski; Hideki Makishima; Aaron D Viny; Isabell Bretschneider; Mohammad Shaik; Nelli Bejanyan; Alan E Lichtin; Eric D Hsi; Eric D His; Ronald L Paquette; Thomas P Loughran; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-08-24       Impact factor: 22.113

2.  A Case of Epstein-Barr Virus-associated Hydroa Vacciniforme.

Authors:  Sun Young Huh; Mira Choi; Kwang Hyun Cho
Journal:  Ann Dermatol       Date:  2009-05-31       Impact factor: 1.444

3.  Hydroa vacciniforme-like lymphoproliferative disorder in Korea.

Authors:  Byeol Han; Keunyoung Hur; Jungyoon Ohn; Tae Min Kim; Yoon Kyung Jeon; You Chan Kim; Je-Ho Mun
Journal:  Sci Rep       Date:  2020-11-09       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.